Monday, June 30, 2025 12:03:41 PM
“Powerless.” Right. The same woman who dragged a 10-patient academic pilot through a 331-patient, placebo-controlled, double-blind Phase 3 in glioblastoma while surviving short attacks, NIH gatekeeping, an SEC case, and a global pandemic.
The same woman who built GMP manufacturing from scratch on two continents, automated it, and filed a marketing application for a personalized cell therapy before big pharma even figured out how to spell “PICV.”
But yeah, let’s ignore all that because in 2011 she said 18–24 months and it turned into 14 years. Meanwhile, Pfizer’s out here paying $43 billion for Seagen and still doesn’t have a glioblastoma plan.
Timing is fair game. Disrespect isn’t. You don’t have to like her but pretending this was a nothingburger company run by a clueless lawyer just makes you look unserious.
The same woman who built GMP manufacturing from scratch on two continents, automated it, and filed a marketing application for a personalized cell therapy before big pharma even figured out how to spell “PICV.”
But yeah, let’s ignore all that because in 2011 she said 18–24 months and it turned into 14 years. Meanwhile, Pfizer’s out here paying $43 billion for Seagen and still doesn’t have a glioblastoma plan.
Timing is fair game. Disrespect isn’t. You don’t have to like her but pretending this was a nothingburger company run by a clueless lawyer just makes you look unserious.
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
